EFFECTS OF ERYTHROPOIESIS-STIMULATING AGENTS ON OVERALL SURVIVAL OF IPSS LOW/INT-1 RISK TRANSFUSION INDEPENDENT MYELODYSPLASTIC SYNDROMEPATIENTS, A FISM STUDY

被引：0
|
作者：
Messa, E. [1 ]
Gioia, D. [2 ]
Masiera, E. [2 ]
Castiglione, A. [3 ]
Ceccarelli, M. [3 ]
Salvi, F. [4 ]
Danise, P. [5 ]
Sanna, A. [6 ]
Allione, B. [7 ]
Balleari, E. [8 ]
Poloni, A. [9 ]
Cametti, G. [1 ]
Ferrero, D. [7 ]
Tassara, R. [10 ]
Finelli, C. [11 ]
Bonferroni, M. [12 ]
Ciccone, G. [3 ]
Saglio, G. [13 ]
Levis, A. [2 ]
Santini, V. [6 ]
机构：
[1] ASLTO 5, Dept Internal Med, Turin, Italy
[2] Fdn Italiana Sindromi Mielodisplast Onlus, Hematol, Alessandria, Italy
[3] Azienda Osped Univ Citta Salute & Sci Torino, Piedmont Reference Ctr Canc Epidemiol & Prevent, Turin, Italy
[4] SS Antonio & Biagio Hosp, Hematol Dept, Alessandria, Italy
[5] ASL Salerno, Div Oncohematol Nocera Pagani, Salerno, Italy
[6] Azienda Osped Univ Careggi, Div Hematol, Florence, Italy
[7] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[8] IRCCS San Martino, Internal Med Dept, Genoa, Italy
[9] Osped Riuniti, Hematol Dept, Ancona, Italy
[10] ASL2 Savonese, Div Med & Hematol, Savona, Italy
[11] St Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy
[12] Santa Croce & Carle Hosp, Div Hematol, Cuneo, Italy
[13] Mauriziano Hosp, Div Hematol, Turin, Italy
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30206-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
93
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [1] Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study
    Messa, Emanuela
    Gioia, Daniela
    Masiera, Elisa
    Castiglione, Anna
    Ceccarelli, Manuela
    Salvi, Flavia
    Danise, Paolo
    Sanna, Alessandro
    Allione, Bernardino
    Balleari, Enrico
    Poloni, Antonella
    Cametti, Giovanni
    Ferrero, Dario
    Tassara, Rodolfo
    Finelli, Carlo
    Bonferroni, Margherita
    Musto, Pellegrino
    Saglio, Giuseppe
    Levis, Alessandro
    Santini, Valeria
    HAEMATOLOGICA, 2019, 104 (01) : E4 - E8
  • [2] Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS
    Pawlikowska, P.
    Kosmider, O.
    Park, S.
    Bardet, V.
    Kuhnowsky, F.
    Pierre-Eugene, C.
    Picard, F.
    Viallon, V.
    Viguie, F.
    Mayeux, P.
    Lacombe, C.
    Porteu, F.
    Dreyfus, F.
    Fontenay, M.
    LEUKEMIA RESEARCH, 2009, 33 : S51 - S52
  • [3] Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge)
    Fenaux, Pierre
    Raza, Azra
    Vellenga, Edo
    Platzbecker, Uwe
    Santini, Valeria
    Samarina, Irina
    Van Eygen, Koen
    Diez-Campelo, Maria
    Patnaik, Mrinal M.
    Sherman, Laurie
    Sun, Libo
    Varsos, Helen
    Rose, Esther
    Rizo, Aleksandra
    Steensma, David P.
    BLOOD, 2017, 130
  • [4] p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes
    Frisan, Emilie
    Pawlikowska, Patrycja
    Pierre-Eugene, Cecile
    Viallon, Vivian
    Gibault, Laure
    Park, Sophie
    Mayeux, Patrick
    Dreyfus, Francois
    Porteu, Francoise
    Fontenay, Michaela
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1964 - 1968
  • [5] Role of Erythropoiesis-Stimulating Agents (ESAs) in Supportive Care of Low-Risk Myelodysplastic Syndromes
    Cerchione, Claudio
    Alfinito, Fiorella
    Soriente, Ilaria
    D'Arco, Alfonso Maria
    Danise, Paolo
    Cerciello, Giuseppe
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S324 - S325
  • [6] Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study
    Garelius, Hege Kristin Gravdahl
    Bagguley, Timothy
    Taylor, Adele
    Fenaux, Pierre
    Bowen, David
    Symeonidis, Argiris
    Mittelmann, Moshe
    Stauder, Reinhard
    Cermak, Jaroslav
    Sanz, Guillermo
    Langemeijer, Saskia
    Malcovati, Luca
    Germing, Ulrich
    Sanhes, Laurence
    d'Aveni, Maud
    Culligan, Dominic
    Kotsianidis, Ioannis
    Koinig, Karin A.
    van Marrewijk, Corine
    Crouch, Simon
    Dewitte, Theo
    Smith, Alexandra
    Hellstroem-Lindberg, Eva
    LANCET HAEMATOLOGY, 2025, 12 (02): : e128 - e137
  • [7] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Roberto Castelli
    Riccardo Schiavon
    Valentina Rossi
    Giorgio Lambertenghi Deliliers
    Medical Oncology, 2018, 35
  • [8] Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents
    Castelli, Roberto
    Schiavon, Riccardo
    Rossi, Valentina
    Deliliers, Giorgio Lambertenghi
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [9] Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Sekeres, Mikkael A.
    List, Alan F.
    Khoury, H. Jean
    Advani, Anjali
    Jabbour, Elias
    Kantarjian, Hagop M.
    Lancet, Jeffrey E.
    Cable, LouAnn
    Guthrie, Kari
    Hogeland, Grant
    Ptaszynski, Mieke
    Maloney, Lara
    Corson, Donald
    Komrokji, Rami S.
    BLOOD, 2013, 122 (21)
  • [10] IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Zeidan, Amer Methqal
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan
    Sherman, Laurie Jill
    Dougherty, Souria
    Sun, Libo
    Huang, Fei
    Wan, Ying
    Rizo, Aleksandra
    Berry, Tymara
    Feller, Faye
    Santini, Valeria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345